Proteintech Unveils Next-Gen 3D Epitope Mapping to Boost Life Sciences Research
Proteintech, a global leader in antibody and life science solutions, is proud to announce the launch of enhanced product characterization for primary antibody targets on its website (ptglab.com). The newly introduced 3D Epitope Mapping offers advanced validation data aimed at improving the efficiency and precision of antibody screening. This cutting-edge technology provides scientists with critical data to support their research, from basic studies to the development of innovative therapeutics.
Proteintech, a global leader in antibody and life science solutions, has unveiled a revolutionary solution for antibody screening and selection: 3D Epitope Mapping. This cutting-edge technology combines advanced experimental methods, including peptide scanning and microbial display, to accurately identify the specific binding site, or epitope, on a targeted protein. The resulting epitope map is then visualized in interactive 3D, using published protein data and artificial intelligence (AI) modeling, providing scientists with a detailed, intuitive representation of antibody binding sites.
The introduction of 3D Epitope Mapping is designed to greatly enhance the efficiency and precision of antibody selection. By visualizing the antibody binding sites in 3D, researchers gain a clearer understanding of how antibodies interact with their target proteins. This detailed visualization significantly accelerates the process of antibody screening, enabling scientists to make more informed decisions when selecting antibodies for their experiments.
Additionally, Proteintech has improved the presentation of immunogenic data on its website. Immunogenicity data, which is crucial for understanding how an antibody may provoke an immune response, is now displayed as a bar graph at the top of product search pages. This allows users to easily identify and select antibodies based on the immunogen of interest, streamlining the selection process.
The combination of 3D Epitope Mapping and improved immunogenic data presentation marks a major advancement for Proteintech’s portfolio. By offering these cutting-edge tools, Proteintech aims to provide researchers with more accurate and efficient means of selecting antibodies, ultimately accelerating the pace of scientific discovery. These tools are particularly important for advancing research in areas like drug development, disease mechanisms, and immune response studies.
“We are thrilled to be the first antibody provider to offer cutting-edge information on products that we believe will have a significant impact on the life sciences community,” said Dr. Jason Li, CEO of Proteintech. “As the original manufacturer of these products, we believe we are uniquely positioned to provide this data to scientists. We expect to have our entire catalog mapped in the near future.” Dr. Li’s statement highlights Proteintech’s commitment to empowering researchers with the best tools available to enhance their work and drive forward medical breakthroughs.
Proteintech’s 3D Epitope Mapping technology offers several key advantages over traditional antibody screening methods. First, it allows scientists to understand precisely where an antibody binds to a protein, which is essential for assessing its effectiveness in research and therapeutic applications. This precision eliminates much of the guesswork associated with selecting antibodies, reducing the time and resources spent testing multiple antibodies for a single experiment.
The ability to visualize epitopes in 3D also provides insight into how antibodies interact with proteins at a molecular level. This deeper understanding of antibody binding can be invaluable in optimizing antibodies for specific applications, whether for diagnostics, therapeutics, or basic research. By leveraging AI modeling in conjunction with experimental techniques, Proteintech ensures that the epitope maps are both accurate and predictive, giving scientists a powerful tool for antibody development.
Moreover, immunogenic data is now more accessible than ever. By displaying this critical information in a bar graph format on product pages, Proteintech makes it easier for researchers to find antibodies that match their specific needs. Whether scientists are studying the immune response or designing experiments that require specific immunogenic characteristics, this feature helps streamline the selection process, allowing researchers to focus on what matters most—advancing science.
Proteintech’s dedication to improving the antibody selection process reflects the company’s broader mission to accelerate scientific discovery and improve human health. As a company that manufactures its own antibodies, proteins, nanobodies, and immunoassays, Proteintech is uniquely positioned to offer these cutting-edge solutions. The company’s portfolio covers a vast range of research areas, from basic biology to cancer research, and Proteintech’s continuous investment in innovation ensures that researchers have access to the best tools available.
About Proteintech
Founded in 2001, Proteintech Group Inc. is a leading manufacturer of antibodies, proteins, nanobodies, and immunoassays. The company boasts the most comprehensive proprietary portfolio of home-grown antibodies, covering approximately two-thirds of the human proteome. With over 300,000 products listed, Proteintech offers antibodies and immunoassays for every area of research. In addition, Proteintech produces bioactive, cGMP-grade cytokines, growth factors, and other human-expressed proteins, ensuring high-quality reagents for a wide range of applications. Proteintech’s facilities are ISO13485 and ISO9001 certified, underscoring its commitment to quality and scientific advancement.
Proteintech’s 3D Epitope Mapping is just the latest example of the company’s ongoing dedication to supporting scientific progress. By combining advanced experimental techniques with cutting-edge visualization tools, Proteintech is providing researchers with the data they need to accelerate their work and push the boundaries of what’s possible in life sciences. The company’s commitment to innovation, along with its unparalleled expertise in antibody development, makes it an invaluable partner for scientists and researchers worldwide.
